Explore

Trendline Trendline
Oral Wegovy: A New Option for Weight Management with Considerations

Oral Wegovy: A New Option for Weight Management with Considerations

Oral Wegovy: A New Option for Weight Management with Considerations
Reuters Reuters
Eli Lilly's weight-loss pill secures first European nod in Britain

Eli Lilly's weight-loss pill secures first European nod in Britain

By Padmanabhan Ananthan Aug 10 (Reuters) - Britain's medicines regulator on Monday authorised Eli Lilly's pill Foundayo for weight management and type 2 diabetes, making it the first country in Europe to green light the treatment.
Trendline Trendline
Novo Nordisk Faces Production Challenges Amid Rising Demand for Wegovy

Novo Nordisk Faces Production Challenges Amid Rising Demand for Wegovy

Novo Nordisk Faces Production Challenges Amid Rising Demand for Wegovy
Reuters Reuters
Hims & Hers raises annual revenue forecast on strong subscriber growth

Hims & Hers raises annual revenue forecast on strong subscriber growth

NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday raised its annual revenue forecast and said it beat second-quarter revenue estimates, as the telehealth company benefited from an increase in subscribers and expanding its personalized healthcare offerings.
Trendline Trendline
Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues

Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues

Sanofi Faces Drug Shortage for Pompe Disease Amid Manufacturing Issues
Trendline Trendline
Wegovy Pill Approved in UK for Weight Loss: A New Option for Patients

Wegovy Pill Approved in UK for Weight Loss: A New Option for Patients

Wegovy Pill Approved in UK for Weight Loss: A New Option for Patients
Rapid Read Rapid Read
FDA Approvals Propel Cellular Gene Therapy Forward

FDA Approvals Propel Cellular Gene Therapy Forward

The FDA has approved over 40 cellular and gene therapy products, marking significant progress in the field. Recent approvals include treatments for rare genetic disorders and advancements in CAR T-cell therapy for cancer. The regulatory landscape is evolving to facilitate faster access to these therapies, which aim to provide curative solutions rather than just symptom management. The focus is on precision medicine, targeting the root causes of diseases with advanced genetic tools.
Trendline Trendline
GLP-1 Medications Transforming Health Beyond Weight Loss

GLP-1 Medications Transforming Health Beyond Weight Loss

GLP-1 Medications Transforming Health Beyond Weight Loss
Trendline Trendline
Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials
Trendline Trendline
Dihydroberberine Shows Enhanced Bioavailability Over Berberine in Supplement Market

Dihydroberberine Shows Enhanced Bioavailability Over Berberine in Supplement Market

Dihydroberberine Shows Enhanced Bioavailability Over Berberine in Supplement Market
TheStreet TheStreet
Key HIV stat over 70% leaves BofA siding with Gilead

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was one of them. The ...
Rapid Read Rapid Read
FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

The U.S. Food and Drug Administration has approved mFLUSIVA, the first mRNA-based flu vaccine for adults aged 50 and older, ahead of the 2026-2027 flu season. The vaccine, developed by Moderna, received full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, with a requirement for further confirmatory trials. This approval marks a significant milestone in vaccine technology, offering a new option for flu prevention in older adults. The mRNA platform allows for faster production and potential updates to better match circulating flu strains.